Liraglutide Standard

Chemical name: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(gamma-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH // Synonyms: N26-(Hexadecanoyl-gamma-glutamyl)-(34-arginine)GLP-1-(7-37), Lys(gamma-Glu-palmitoyl)26,Arg34)-GLP-1 (7-37), ), One letter Code:HAEGTFTSDVSSYLEGQAAK(gamma-Glu-palmitoyl)EFIAWLVRGRG

  • Product code:LS-4051
  • CAS No.:204656-20-2
  • Formula:C172H265N43O51
  • Molecular weight:3751.26 g/mol
  • Purity :min. 99.0%, no single impurity

Starting at Please inquire

Grouped product items
Qty Packing unit Price SKU
2,5 mg
Please inquire
Safety Data Sheets

20mg per vial net peptide content, as peptide standard for quantitative analysis. Glucagon-Like-Peptide-1 (GLP-1) agonist used for the treatment of type 2 diabetes. It is an incretin mimetic stimulating the release and synthesis of insulin into the blood by the intestine in response to food. It is only active in the presence of high circulating glucose levels. It also slows the passage of food through the gut and reduces appetite.


Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide; I. Guryanov, A. Bondesan, D. Visentini, A. Orlandin, B. Biondi, C. Toniolo, F. Formaggio, A. Ricci, J. Zanon and W. Cabri; J Pept Sci 2016; 22: 471-9.

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide; J. Lau, P. Bloch, L. Schäffer, I. Pettersson, J. Spetzler, J. Kofoed, K. Madsen, L. B. Knudsen, J. McGuire, D. B. Steensgaard, H. M. Strauss, D. X. Gram, S. M. Knudsen, F. S. Nielsen, P. Thygesen, S. Reedtz-Runge and T. Kruse; Journal of medicinal chemistry 2015; 58: 7370-7380.

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates; C. F. Gotfredsen, A. M. Molck, I. Thorup, N. C. Nyborg, Z. Salanti, L. B. Knudsen and M. O. Larsen; Diabetes 2014; 63: 2486-97.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors; J. J. Neumiller; J Am Pharm Assoc (2003) 2009; 49 Suppl 1: S16-29.

Liraglutide in type 2 diabetes: from pharmacological development to clinical practice; M. C. Rossi and A. Nicolucci; Acta Biomed 2009; 80: 93-101.

Potential of liraglutide in the treatment of patients with type 2 diabetes; C. F. Deacon; Vasc Health Risk Manag 2009; 5: 199-211.

Bulk or large quantity order?

Do you need larger quantities for your development or production?

Do you need further information about this product?

get in contact

Quick contact

Please send me more information about

We found other products you might like!